Björn Redfors

University of Gothenburg
Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

BACKGROUND: Limited data are available regarding the relative rates, etiology, and long-term prognostic implications of spontaneous myocardial infarction (MI) after percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery for left main coronary artery disease (LMCAD). METHODS: MIs after PCI and CABG for LMCAD were adjudicated from the EXCEL trial (Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization). Cox proportional hazards regression was performed to assess the association between spontaneous (and procedural) MI and cardiovascular and all-cause mortality at 5 years. RESULTS: Among 1882 patients who underwent LMCAD revascularization, spontaneous MI during 5-year follow-up occurred in 60 (6.8%) patients after PCI and in 29 (3.4%) patients after CABG (adjusted hazard ratio [adjHR], 2.01; 95 CI, 1.29–3.15; P =0.002). By multivariable analysis, spontaneous MI (as a time-adjusted covariate) was a strong independent predictor of subsequent cardiovascular mortality (adjHR, 9.39; 95% CI, 5.22–16.87) and all-cause mortality (adjHR, 4.77; 95% CI, 2.92–7.80) within 5 years, with consistent effects after PCI and CABG ( P interaction =0.60 and 0.78, respectively). In the same models, procedural MI as defined by extensive myonecrosis was associated with 5-year cardiovascular (adjHR, 3.02; 95% CI, 1.64–5.56) and all-cause mortality (adjHR, 2.38; 95% CI, 1.48–3.80), with consistent effects after PCI and CABG ( P interaction =0.23 and 0.34, respectively). CONCLUSIONS: In the EXCEL trial, spontaneous MI occurred relatively infrequently within 5 years after LMCAD revascularization but at a higher rate after PCI compared with CABG. Spontaneous MI after revascularization was strongly related to subsequent cardiovascular and all-cause mortality, consistently after PCI and CABG, and was more strongly associated with mortality than was large procedural MI.

Year:

2026

BACKGROUND: The treatment of calcified coronary lesions requires optimal lesion preparation to achieve a larger minimal stent area (MSA), the strongest predictor of long-term outcomes. The comparative mechanisms of action of calcium-modifying therapies have not been well defined. METHODS: In a prospective, multicenter ECLIPSE trial (Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy Versus Conventional Angioplasty Technique Before Implantation of Drug-Eluting Stents), 2005 patients with severely calcified lesions were randomized to vessel preparation with orbital atherectomy (OA) versus balloon angioplasty (BA) before drug-eluting stent implantation. The primary end point of the optical coherence tomography (OCT) substudy was the MSA at the site of maximal calcification; MSA across the entire stent was also assessed. RESULTS: Postprocedural OCT images were available in 286 lesions in 276 patients treated with OA and 292 lesions in 279 patients treated with BA. By angiographic core laboratory analysis, 567 (98.1%) of lesions were severely calcified. By postprocedural OCT, the maximal calcium arc, maximal calcium thickness, and total calcium length measured 204° (149°–268°), 0.85 mm (°0.69–1.03°), and 22.0 (16.0–31.0) mm. Compared with BA, calcium modification was greater in the OA group (greater number, total length, and maximal depth of calcium fractures), especially in lesions with thicker calcium. Nonetheless, the MSA at the site of maximal calcification was large in both groups and not different (median [interquartile range], 7.44 [6.03–8.94] mm 2 versus 7.05 [5.78–8.66] mm 2 ; P =0.08). Similar results were observed for the MSA across the entire stent (5.86 [4.60–7.38] mm 2 versus 5.57 [4.50–6.97] mm 2 ; P =0.10). Among patients in the OCT substudy, 1-year target-vessel failure rates were low and not different between the groups (7.8% with OA and 6.6% with BA, P =0.61). CONCLUSIONS: In lesions that are severely calcified by angiography, the extent of calcification by OCT was highly variable. Despite greater calcium modification after OA, the acute MSA and 1-year target-vessel failure rates were not different between OA and BA. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03108456.

Year:

2026

OBJECTIVES Postoperative atrial fibrillation (POAF) is the most common complication following cardiac surgery and is associated with prolonged in-hospital stay and increased costs, morbidity (including stroke and heart failure) and mortality. Posterior pericardiotomy (PP) is a surgical intervention aimed at draining the pericardium into the left pleural cavity to reduce POAF occurrence. This review summarizes the current evidence on the use of PP and highlights future perspectives for clinical research. METHODS The present work is a narrative review, a systematic literature search was therefore not performed. After collegial discussion, the most relevant papers as per the authors’ opinion were selected and formed the basis of the present review. RESULTS Several studies support the hypothesis that PP decreases the incidence of POAF, pericardial effusion and cardiac tamponade after cardiac surgery. Although an increased incidence of pleural effusion has been reported after PP, this finding does not translate into increased pulmonary complications. Whether the systematic use of PP during cardiac surgery improves long-term outcomes is unclear. CONCLUSIONS PP is a simple and safe technique that holds the potential to positively impact cardiac surgical patients’ postoperative course. The results of upcoming, multicentre trials will help shed definitive light on this topic.

Year:

2025

Background The BIONICS (BioNIR Ridaforolimus‐Eluting Coronary Stent System in Coronary Stenosis) and the NIREUS (BioNIR Ridaforolimus Eluting Coronary Stent System [BioNIR] European Angiography Study) randomized clinical trials showed noninferiority of the ridaforolimus‐eluting stent (RES) compared with the zotarolimus‐eluting stent (ZES) with respect to 1‐year target‐lesion failure and 6‐month angiographic late lumen loss. We aimed to evaluate clinical outcomes between treatment groups over a 5‐year follow‐up. Methods and Results Patient‐level data from the BIONICS (n=1919) and NIREUS (n=302) were pooled, comparing the outcomes of patients implanted with RES and ZES. The primary end point was the 5‐year rate of target‐lesion failure. A total of 2221 patients (63.2±10.3 years, 79.7% men) undergoing percutaneous coronary intervention with RES (n=1159) or ZES (n=1062) were included. Most clinical and angiographic characteristics were similar between groups. At 5 years, the primary end point of target‐lesion failure was similar between treatment groups (12.2% RES versus 11.3% ZES, P =0.52). Rates of TLR (7.6% RES versus 6.8% ZES, P =0.42) target‐vessel–related myocardial infarction (4.8% RES versus 4.9% ZES, P =0.95) and stent thrombosis (0.9% RES versus 0.9% ZES, P =0.87) also did not differ between groups. Target‐vessel revascularization and cardiac death were higher among the RES group (12.3% versus 9.5% P =0.037, and 3.6% versus 2.2% P =0.042, respectively). However, after correction for baseline characteristics, there was no significant difference in cardiac death between groups. Conclusions In a pooled analysis of 2 randomized trials, 5‐year clinical outcomes were similar between patients undergoing percutaneous coronary intervention with RES and ZES. These results support the long‐term safety and efficacy of RES for the treatment of patients with coronary artery disease.

Year:

2024

Background The use of inotropic agents in treating cardiogenic shock (CS) remains controversial. We aimed to investigate the effect of treatment with inotropes on 30-day mortality in patients with CS from the SWEDEHEART registry (The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies). Methods We used data from the national SWEDEHEART registry on all patients diagnosed with CS in Sweden between 2000 and 2022. The primary endpoint was 30-day all-cause mortality. We used multilevel Cox proportional-hazards regression with instrumental variable and inverse probability weighting propensity score to adjust for known and unknown confounders. The treatment-preference instrument was the quintile of preference for using inotropes at the treating hospital. Results In total, 16,214 patients (60.5% men and 39.5% women) were included; 23.5% had diabetes, 10.2% had a previous myocardial infarction (MI), and 13.8% had previous heart failure (HF). The median age was 70 years (interquartile range; 19), and 66.4% were >70. Acute coronary syndrome (ACS) was the cause of CS in 82.9% of patients. Inotropic agents were used in 43.8% of patients, while 56.2% did not receive inotropic agents. There were 7,875 (48.1%) deaths. On average, patients treated with inotropes were two years younger and more likely to have ACS. Patients not treated with inotropes were more likely to have previous MI and previous PCI but less likely to undergo PCI. The number of patients with CS decreased by 12% per year (P trend <0.001). There was a considerable variation between hospitals in the preference for using inotropes ranging from 25 to 78% (P<0.001). Inotropes increased by 5% per year (P trend <0.001). The unadjusted mortality in CS increased by 2% per calendar year (P trend <0.001). The risk of death was higher in patients treated with inotropes [adjusted hazard ratio (HR adj ) 1.72; 95% confidence interval (CI) 1.26-2.35; P=0.001]. There was a quantitative interaction between inotrope treatment and age and diagnosis (P interaction < 0.001 and P interaction = 0.018, respectively). Conclusions In this observational study, using inotropes was associated with a higher mortality risk in patients with CS. The increased risk of death was more pronounced in patients younger than 70. The number of patients with CS is decreased, while the use of inotropes and mortality increased in Sweden.

Year:

2024

Individual patient data (IPD) meta-analyses build upon traditional (aggregate data) meta-analyses by collecting IPD from the individual studies rather than using aggregated summary data. Although both traditional and IPD meta-analyses produce a summary effect estimate, IPD meta-analyses allow for the analysis of data to be performed as a single dataset. This allows for standardization of exposure, outcomes, and analytic methods across individual studies. IPD meta-analyses also allow the utilization of statistical methods typically used in cohort studies, such as multivariable regression, survival analysis, propensity score matching, uniform subgroup and sensitivity analyses, better management of missing data, and incorporation of unpublished data. However, they are more time-intensive, costly, and subject to participation bias. A separate issue relates to the meta-analytic challenges when the proportional hazards assumption is violated. In these instances, alternative methods of reporting time-to-event estimates, such as restricted mean survival time should be used. This statistical primer summarizes key concepts in both scenarios and provides pertinent examples.

Year:

2024

Aims Cardiac troponin T (cTnT) and troponin I (cTnI) are expressed as an obligate 1:1 complex in the myocardium. However, blood levels of cTnI often rise much higher than that of cTnT in myocardial infarction (MI), whereas cTnT is often higher in patients with stable conditions such as atrial fibrillation. Here we examine high-sensitive (hs) cTnI and hs-cTnT after different durations of experimental cardiac ischaemia. Methods and results hs-cTnI, hs-cTnT, and the hs-cTnT/hs-cTnI ratio were measured in plasma samples from rats before and at 30 and 120 min after 5, 10, 15, and 30 min of myocardial ischaemia. The animals were killed after 120 min of reperfusion, and the infarct volume and volume at risk were measured. hs-cTnI, hs-cTnT, and the hs-cTnT/hs-cTnI ratio were also measured in plasma samples collected from patients with ST-elevation myocardial infarction (STEMI). hs-cTnT and hs-cTnI increased over 10-fold in all rats subjected to ischaemia. The increase of hs-cTnI and hs-cTnT after 30 min was similar, resulting in a hs-cTnI/hs-cTnT ratio around 1. The hs-cTnI/hs-cTnT ratio was also around 1 in blood samples collected at 120 min in rats subjected to 5 or 10 min of ischaemia where no localized necrosis was observed. In contrast, the hs-cTnI/hs-cTnT ratio at 2 h was 3.6–5.5 after longer ischaemia that induced cardiac necrosis. The large hs-cTnI/hs-cTnT ratio was confirmed in patients with anterior STEMI. Conclusion Both hs-cTnI and hs-cTnT increased similarly after brief periods of ischaemia that did not cause overt necrosis, whereas the hs-cTnI/hs-cTnT ratio tended to increase following longer ischaemia that induced substantial necrosis. A low hs-cTnI/hs-cTnT ratio around 1 may signify non-necrotic cTn release.

Year:

2023

Collaborators (14)

Elmir Omerovic

Chair Professor of Cardiology

University of Gothenburg

SWEDEN
View details

Akiko Maehara

-

UNITED STATES
View details

Ole Frobert

Professor

Aarhus University

DENMARK
View details

Sigrid Sandner

Medical University of Vienna

AUSTRIA
View details

Tomas Jernberg

Professor

Karolinska Institutet

SWEDEN
View details

Gregg W. Stone

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

David Erlinge

Lund University

SWEDEN
View details

Joakim Alfredsson

Linköping University

SWEDEN
View details

Patrick W. Serruys

Professor of Interventional Medicine and Innovation

University of Galway

IRELAND
View details

Stuart Pocock

Professor of Medical Statistics

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Giuseppe Biondi-Zoccai

Associate Professor

Sapienza University of Rome

ITALY
View details

Oskar Angerås

Karolinska University Hospital

SWEDEN
View details

Ori Ben-Yehuda

Professor

University of California, San Diego

UNITED STATES
View details

Arie Pieter Kappetein

Prof. Dr

Erasmus MC

NETHERLANDS
View details